the pharmacy hub semaglutide Semaglutide Oral Semaglutide - Research Peptide -
Description
[12] Post-marketing surveillance data from the FDA Adverse Event Reporting System (FAERS) indicate that serious hepatic adverse events with semaglutide are rare, though such spontaneous reporting systems have inherent limitations and cannot establish true incidence or definitive causality
In metabolic dysfunction-associated steatohepatitis with moderate to advanced fibrosis, semaglutide improved liver histology over 72 weeks
About this article Cite this article Kim, J., Kim, K., Lee, T.S
As with any medication, they can have side effects
